Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Burke

Showing results (31-40 of 85) with videos related to

Pageof 9
Sort By:
Cytokine & Growth Factor Reviews|May 18, 2010
Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approvalCaroline J Breitbach, Tony Reid, James Burke, et al.
Methods in Molecular Biology (Clifton, N.J.)|June 15, 2015
A Phase 2, Open-Label, Randomized Study of Pexa-Vec (JX-594) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular CarcinomaCaroline J Breitbach, Anne Moon, James Burke, et al.
Circulation. Cardiovascular Quality and Outcomes|July 18, 2024
Estimating the Impact of Hospital-Level Variation on the Use of Inpatient Rehabilitation Facilities Versus Skilled Nursing Facilities on Individual Patients With StrokeKent P Simmonds, James Burke, Alan Kozlowski, et al.
Oncolytic Virotherapy|August 12, 2016
The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594)Caroline J Breitbach, John C Bell, Tae-Ho Hwang, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|October 19, 2018
Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target TissuesJennifer R Seal, Michael R Robinson, James Burke, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 20, 2002
Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyesAndrew A Acheampong, Martha Shackleton, Brian John, et al.
Archives of Physical Medicine and Rehabilitation|March 4, 2022
Emulating 3 Clinical Trials That Compare Stroke Rehabilitation at Inpatient Rehabilitation Facilities With Skilled Nursing FacilitiesKent P Simmonds, James Burke, Allan J Kozlowski, et al.
Archives of Physical Medicine and Rehabilitation|September 4, 2021
Rationale for a Clinical Trial That Compares Acute Stroke Rehabilitation at Inpatient Rehabilitation Facilities to Skilled Nursing Facilities: Challenges and OpportunitiesKent P Simmonds, James Burke, Allan J Kozlowski, et al.
Acta Neuropathologica Communications|March 4, 2022
Tuberous sclerosis complex is a novel, amyloid-independent tauopathy associated with elevated phosphorylated 3R/4R tau aggregationAndy J Liu, Jay B Lusk, John Ervin, et al.
Current Opinion in Virology|April 23, 2015
Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeuticCaroline J Breitbach, Kelley Parato, James Burke, et al.
Pageof 9

Showing results (31-40 of 85) with videos related to

Sort By:
Pageof 9
Cytokine & Growth Factor Reviews|May 18, 2010
Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approvalCaroline J Breitbach, Tony Reid, James Burke, et al.
Methods in Molecular Biology (Clifton, N.J.)|June 15, 2015
A Phase 2, Open-Label, Randomized Study of Pexa-Vec (JX-594) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular CarcinomaCaroline J Breitbach, Anne Moon, James Burke, et al.
Circulation. Cardiovascular Quality and Outcomes|July 18, 2024
Estimating the Impact of Hospital-Level Variation on the Use of Inpatient Rehabilitation Facilities Versus Skilled Nursing Facilities on Individual Patients With StrokeKent P Simmonds, James Burke, Alan Kozlowski, et al.
Oncolytic Virotherapy|August 12, 2016
The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594)Caroline J Breitbach, John C Bell, Tae-Ho Hwang, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|October 19, 2018
Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target TissuesJennifer R Seal, Michael R Robinson, James Burke, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 20, 2002
Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyesAndrew A Acheampong, Martha Shackleton, Brian John, et al.
Archives of Physical Medicine and Rehabilitation|March 4, 2022
Emulating 3 Clinical Trials That Compare Stroke Rehabilitation at Inpatient Rehabilitation Facilities With Skilled Nursing FacilitiesKent P Simmonds, James Burke, Allan J Kozlowski, et al.
Archives of Physical Medicine and Rehabilitation|September 4, 2021
Rationale for a Clinical Trial That Compares Acute Stroke Rehabilitation at Inpatient Rehabilitation Facilities to Skilled Nursing Facilities: Challenges and OpportunitiesKent P Simmonds, James Burke, Allan J Kozlowski, et al.
Acta Neuropathologica Communications|March 4, 2022
Tuberous sclerosis complex is a novel, amyloid-independent tauopathy associated with elevated phosphorylated 3R/4R tau aggregationAndy J Liu, Jay B Lusk, John Ervin, et al.
Current Opinion in Virology|April 23, 2015
Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeuticCaroline J Breitbach, Kelley Parato, James Burke, et al.
Pageof 9